Urologische Klinik

The Involvement of Cx43 in JNK1/2-Mediated Endothelial Mechanotransduction and Human Plaque Progression (2023) Tauchi M, Oshita K, Urschel K, Furtmair R, Kühn C, Stumpfe F, Botos B, et al. Journal article Editorial: Cutting edge basic and clinical bladder cancer research – the IBCN updates (2023) Goebell P, Kamat AM, Black PC, Dyrskjøt L, Nawroth R, Seiler R, Todenhöfer T, et al. Journal article, Review article Retrospective histological evaluation of orchiectomy specimens following testicular torsion reveals a 10% incidence of reversible injury. Is it time for a change of strategy? (2022) Marcou M, Hartmann A, Wullich B, Apel H, Hirsch-Koch K Journal article A genome-wide association study with tissue transcriptomics identifies genetic drivers for classic bladder exstrophy (2022) Mingardo E, Beaman G, Grote P, Nordenskjöld A, Newman W, Woolf AS, Eckstein M, et al. Journal article Efficacy of cabazitaxel in fourth or later line of therapy in metastatic castration-resistant prostate cancer: Multi-institutional real-world experience in Germany (2022) Wenzel M, Borkowetz A, Lieb V, Hoffmann MA, Borgmann H, Höfner T, Dotzauer R, et al. Journal article Expression of nectin-4 in papillary renal cell carcinoma (2022) Zschabitz S, Mikuteit M, Stoehr C, Herrmann E, Polifka I, Agaimy A, Trojan L, et al. Journal article Thrombospondin-2 and LDH: potential predictive biomarkers for the treatment of metastatic renal cell carcinoma with everolimus after one VEGF-targeted therapy (MARC-2 study) (2022) Zeuschner P, Hoelters S, Stoeckle M, Seliger B, Mueller A, Bachmann HS, Gruenwald V, et al. Conference contribution Sequential treatment patterns over time for advanced renal cell carcinoma: data from the German research platform CARAT (2022) Goebell P, Gruellich C, Mueller L, Boegemann M, Martens U, Von Der Heyde E, Reichert D, et al. Conference contribution Early CRP kinetics predict long-term treatment success and favorable outcomes of anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma (2022) Klümper N, Sikic D, Saal J, Buettner T, Jarczyk J, Zeuschner P, Weinke M, et al. Conference contribution A prospective, open-label, multicenter, randomized phase II trial: Sequential therapy with BEvacizumab, RAd001 (Everolimus) and AxiTinib in metastatic renal cell carcinoma (mRCC) (BERAT study of the IAG-N) (2022) Hilser T, Gruenwald V, Bergmann L, Goebell P, Strauss A, Meiler J, Hartmann A, et al. Conference contribution